Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an inherited disorder associated with a malfunction of an enzyme that plays a key role in glucose metabolism. This enzyme is involved in the process of oxidative phosphorylation and is vital for maintaining NADPH levels, which are necessary for protecting cells from oxidative stress. Patients with G6PD deficiency have increased sensitivity to various factors, including some medications, infectious diseases and certain foods, which can lead to hemolysis of red blood cells and clinical manifestations such as anemia, jaundice and fatigue. The disease has a polyetiological nature and can manifest itself in varying degrees of severity, which makes it an important topic for medical research and practice.
History of the disease and interesting historical facts
G6PD deficiency was first described in 1956, when researchers found a link between this enzyme deficiency and hemolytic anemia. The most interesting historical fact is that in the 1970s, the genetic nature of this disorder was established, opening up new horizons for understanding inherited metabolic disorders. It is also known that G6PD deficiency is more common in people of African descent and in people of Mediterranean origin, making this disorder an interesting object of study in the context of evolutionary biology.
Epidemiology
Glucose-6-phosphate dehydrogenase deficiency has different prevalence rates in different populations. In global practice, the statistics are as follows:
- In African populations - from 10% to 25%
- The Jewish population has about 10%
- In Mediterranean countries - 5% - 15%
The condition may also occur in up to 1 in 10,000 newborns in some areas, highlighting its public health importance and the need for early diagnosis.
Genetic predisposition to this disease
Genetic predisposition to G6PD deficiency is associated with mutations in the G6PD gene, located on the X chromosome. More than 400 different mutations are known, each causing variations in enzyme activity. The most common mutations include:
- G6PD A- (Denyak form)
- G6PD Mediterranean (Mediterranean form)
- G6PD Canton
Men who have one copy of the mutant gene on the X chromosome are at higher risk of the disease, while women who have two X chromosomes may have some protection from having one normal copy of the gene.
Risk factors for the development of this disease
Risk factors for G6PD deficiency can be divided into two categories: physical and chemical. Physical factors include:
- Infections
- Physical activity
- Hypoxic conditions
Chemical factors include:
- Some medications (examples: sulfonamides, aspirin)
- Certain foods (eg fava beans)
- Toxic substances (including insecticides)
Storage of blood with low G6PD levels may also become an additional predisposing factor for the manifestation of the disease.
Diagnosis of this disease
Diagnosis of glucose-6-phosphate dehydrogenase deficiency involves a number of clinical and laboratory tests. The main symptoms may vary, but the most common are:
- Anemia
- Jaundice
- Fatigue
Laboratory tests include:
- Determination of hemoglobin level
- General blood analysis
- Specific tests for G6PD activity
Radiological examinations are generally not required, but in some cases they can be used to evaluate the condition of internal organs in the presence of anemia. Differential diagnosis includes exclusion of other forms of hemolytic anemia and blood diseases.
Treatment
Treatment of G6PD deficiency depends on the severity of symptoms and clinical picture. In case of mild form of the disease, observation and avoidance of triggers (infections, some medications) may be enough. The main approaches to treatment include:
- General treatment: Maintain hemoglobin levels with diet and prevent hemolysis
- Pharmacological treatment: use of corticosteroids in cases of severe hemolytic anemia
- Surgical treatment: may be required in case of complications such as massive hemolysis
- Other treatments: supportive care as needed, including blood transfusion
List of medications used to treat this disease
Drugs used to treat G6PD deficiency include:
- Corticosteroids (eg, prednisolone)
- Iron supplements (in case of anemia)
- Erythropoietin (in some cases to stimulate red blood cell production)
Disease monitoring
Monitoring of G6PD deficiency involves regular follow-up examinations to assess hemoglobin levels and possible signs of hemolysis. The prognosis for patients with mild disease is usually good, but complications such as severe anemia and chronic liver disease may occur in cases of severe hemolysis.
Age-related features of the disease
G6PD deficiency can manifest itself at any age, but clinical manifestations are most pronounced in newborns and children. In adults, the form of the disease is usually less severe, but it is important to consider individual manifestations depending on background diseases and associated factors.
Questions and Answers
- What is G6PD deficiency? It is an inherited disorder caused by a deficiency in an enzyme that protects red blood cells from oxidative stress.
- What are the main symptoms of the disease? The main symptoms include anemia, jaundice and fatigue.
- How is the disease diagnosed? Diagnostics include a complete blood count and tests for G6PD activity.
- What are the risk factors for the disease? The main risk factors are infections, physical activity and certain medications.
- How is G6PD deficiency treated? Treatment includes supportive care, and in some cases corticosteroids are used.
Dr. Oleg Korzhikov, a specialist in internal medicine, advises: “It is important to understand that with G6PD deficiency, it is necessary to avoid triggers, such as certain medications and foods that promote hemolysis. Regular check-ups and following your doctor’s recommendations will help you cope with the symptoms of the disease and live a full life.”
